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Abstract
Background: There are several known autosomal genes responsible for Ras/MAPK pathway syndromes, including Noonan
syndrome (NS) and related disorders (such as LEOPARD, neurofibromatosis type 1), although mutations of these genes do
not explain all cases. Due to the important role played by the mitochondrion in the energetic metabolism of cardiac muscle,
it was recently proposed that variation in the mitochondrial DNA (mtDNA) genome could be a risk factor in the Noonan
phenotype and in hypertrophic cardiomyopathy (HCM), which is a common clinical feature in Ras/MAPK pathway
syndromes. In order to test these hypotheses, we sequenced entire mtDNA genomes in the largest series of patients
suffering from Ras/MAPK pathway syndromes analyzed to date (n= 45), most of them classified as NS patients (n= 42).
Methods/Principal Findings: The results indicate that the observed mtDNA lineages were mostly of European ancestry,
reproducing in a nutshell the expected haplogroup (hg) patterns of a typical Iberian dataset (including hgs H, T, J, and U).
Three new branches of the mtDNA phylogeny (H1j1, U5b1e, and L2a5) are described for the first time, but none of these are
likely to be related to NS or Ras/MAPK pathway syndromes when observed under an evolutionary perspective. Patterns of
variation in tRNA and protein genes, as well as redundant, private and heteroplasmic variants, in the mtDNA genomes of
patients were as expected when compared with the patterns inferred from a worldwide mtDNA phylogeny based on more
than 8700 entire genomes. Moreover, most of the mtDNA variants found in patients had already been reported in healthy
individuals and constitute common polymorphisms in human population groups.
Conclusions/Significance: As a whole, the observed mtDNA genome variation in the NS patients was difficult to reconcile
with previous findings that indicated a pathogenic role of mtDNA variants in NS.
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Introduction
Noonan syndrome (NS) was first described by Noonan and
Ehmke [1]. It refers to a pleiomorphic autosomal dominant
disorder with short stature, facial dysmorphia, a webbed neck and
heart defects, and its prevalence is about one in 1000–2500 live
births [2]. Cardiovascular diseases including valvular pulmonary
stenosis, atrial septal defect and hypertrophic cardiomyopathy
(HCM) are generally observed in 50–80% of the patients, with
HCM being one of the most common cardiac abnormalities in
these patients [3,4,5,6].
Several germ line gain-of-function mutations in several RAS
pathway members, including PTPN11 (which encode tyrosine
phosphatase SHP-2), KRAS, SOS1, BRAF, and RAF1, SHOC2,
MEK1 (alias MAPP2K1) have been identified as being responsible
for NS [7,8,9,10,11,12]. It has been suggested that nuclear DNA
(nDNA) mutations in PTPN11 account for about ,50% of cases
[13]. Mutations in KRAS, SOS1, and RAF1 make up ,1–2%,
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,20%, and 3–5% of NS cases without PTPN11 mutations,
respectively [14]. When combined, all the above mentioned
nuclear genes would account for 70–85% of NS cases [15]. Thus
far, seven genes have been causally related to NS but also to other
closely related conditions, including LEOPARD syndrome and
Noonan-like syndrome. Germline mutations in a subgroup of
those genes and other genes encoding signal transducers
participating in the same pathway (HRAS, KRAS, NF1, SPRED1,
BRAF, MEK1 and MEK2, alias MAP2K2) have been identified to
be implicated in other clinically related disorders such as Costello
syndrome ore neurofibromatosis type 1 [16]. Some authors
proposed to group these developmental diseases in a single family
of disorders, which has been termed the neurocardiofacialcuta-
neous syndrome (NCFCS) family [16], the Ras/MAPK pathway
syndromes or RASopathies [17].
The search for new causal genes responsible for Ras/MAPK
pathway syndromes has motivated many authors to explore the
potential role of mtDNA mutations in NS and HCM based on the
assumption that the mitochondrion plays an essential role in the
energetic metabolism of cardiac muscle. Thus, recently, Dhanda-
pany et al. [18] reported nine mtDNA mutations in a Noonan
Indian patient suffering hypertrophic obstructive cardiomyopathy.
According to the authors, ‘‘Our case forms the first report, which
emphasizes the importance of mtDNA mutations in Noonan syndrome and
extends the scope for mitochondrial related syndromes’’ (p. 287) [18]. The
study of Dhandapany et al. was based on the analysis of only one
patient’s complete mtDNA genome, and the full set of results was
not reported by the authors: only a list of nine mutations observed
in the patient’s mtDNA genome was reported. Eight of these
mutations were reported as novel, a finding that was interpreted
by the authors as follows: ‘‘the identification of these mutations indicates
that mutations in mtDNA may account for a significant portion of genetic
etiology in Noonan syndrome’’ (p. 287) [18]. A year before the
appearance of the study by Dhandapany’s et al. [18], Prasad et al.
[19] claimed that they had observed six novel mutations in an
Indian HCM patient. Both studies attributed the pathogenic
condition to their presumable ‘‘novel’’ variants without any further
scientific support. The misconception of ‘‘novelty’’ being synon-
ymous with ‘‘causality’’ for mtDNA variants is unfortunately all
too common in medical literature. And this is particularly
problematic in mtDNA studies due to the fact that the mtDNA
molecule is highly variable in human populations; in fact, a large
proportions of both rare and common variations in populations
still remain to be discovered and are consequently unrecorded in
databases. As discussed in Bandelt et al. [20], ‘‘…An observed mtDNA
mutation or polymorphism is novel if it has not been observed before; that is, it
has not been reported in the literature before or cannot be found in other publicly
available source. This, however, is not the manner in which the novelty of
mtDNA mutations is perceived and treated in practice by the working human
geneticist.’’ (p. 1073) [20]. Novelty is almost always operationally
defined by searching for mtDNA in the main reference mtDNA
database in the field, namely, MITOMAP (http://www.mitomap.
org/cgi-bin/mitomap/search.pl) [20]. However, MITOMAP,
although useful for many medical applications, is deficient in few
aspects [20], and has therefore been interpreted as a risk factor in
medical studies [21,22].
Other recent articles have contributed to the debate on the
presumable association of mtDNA variants or haplogroups (hgs) with
NS or HCM. For example, Castro et al. [23] claimed to have found
an association between hg T and NS patients of European ancestry,
while Rani et al. [24] reported a presumable association between hg
R and NS cases in a very small cohort of seven Indian patients.
The present study was motivated by this controversy. We
conducted a sequencing study of the whole mtDNA genome in a
total of 45 patients suffering Ras/MAPK pathway syndromes; most
of them were NS patients (93%). About 11% of the patients were
also affected by HCM. This is the largest cohort of Ras/MAPK
pathway syndromes and Noonan patients who were analyzed for
mtDNA variations by far. An evolutionary approach was carried
out in order to assist the interpretation of variations found in NS
patients. This approach was shown to be very useful in a previous
study dealing with the analysis of mtDNA variation in astheno-
zoospermic males [25]. The alternative method of using a mtDNA
case-control population study would require a much larger sample
size, which is unfeasible for rare traits such as NS [26,27]. We
aimed to address several issues in the present study: (i) to evaluate
whether Ras/MAPK pathway syndromes (with especial focus in NS
patients) cluster in particular hgs by comparing the data with data
available from human populations of the same ancestry, (ii) to
identify mutations that could explain the clinical phenotypes of our
patients, (iii) to evaluate whether replacement substitutions
accumulate to a greater extent in patients with respect to
expectations derived from control individuals (represented by the
worldwide phylogeny based on more than 7800 entire genomes);
(iv) to see whether tRNA mutations are more prevalent in patients
than in control individuals, and (v) to examine recurrent, private
and heteroplasmic mutations for patterns that could explain the
clinical phenotypes. Moreover, previous findings claiming an
association between mtDNA mutations or hgs and NS are
discussed here for the first time in view of the present evolutionary
evidence.
Methods
Ethics statement
Written informed consent was required from all patients.
Analysis of entire mtDNA genomes in patient samples was
approved by the Ethical committee of the University of Santiago
de Compostela. The study conforms to the Spanish Law for
Biomedical Research (Law 14/2007- 3 of July).
Sample collection and DNA extraction
Blood samples were collected from all patients anonymously. A
total of 45 samples were recruited for the present study. Our
samples include 42 NS cases, two LEOPARD syndrome patients,
and one neurofibromatosis type 1 patient. Note however, that the
NS is clinically variable and a genetically heterogeneous
developmental disorder; therefore our collection of patients was
grouped more generally as patients suffering Ras/MAPK pathway
syndromes. Among the 45 patients recruited, we included three
pairs of brothers (namely, patients #15 and #16, #22 and #23,
#25 and #26; see Figure 1). The DNA was extracted following
standard phenol-chloroform protocols. Table 1 summarizes the
clinical-pathological characteristics of our patients.
Complete genome sequencing
The DNA from all patients was sequenced for the entire
mtDNA molecule. We followed the sequencing protocols used by
A´lvarez-Iglesias et al. [28], which are briefly described here. The
primers used for Polymerase Chain Reaction (PCR) amplification
and sequencing were reported previously [29]. Polymerase Chain
Reaction was performed in 10 mL of the reaction mixture,
containing 4 mL of PCR Master Mix (Qiagen; Hilden, Germany),
0.5 mL 1 mM of each primer, 1 mL sample template and 4 mL of
water. This PCR was carried out in a 9700 Thermocycler (AB)
with one cycle of 95uC for 15 min and then 35 cycles of 94uC for
30 s, 58uC for 90 s and 72uC for 90 s with a full extension cycle of
72uC for 10 min. The sequencing reaction was performed in
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Figure 1. Maximum parsimony tree of 45 entire mtDNA genomes of patients suffering Ras/MAPK pathway syndromes. The mutations
are displayed along branches; the variant nomenclature is refered to was taken from the rCRS [30]. All mutations are transitions unless a suffix
specifies a transversion (A, C, G, T), a deletion (d), an insertion (+), a synonymous substitution (s), a mutational change in tRNA (-t), a mutational
change in rRNA (-r), stop codon (-stp), non-coding variant located in the mtDNA coding region (-nc) or amino acid replacement (indicated in round
brackets). Recurrent mutational events are underlined. A prefix indicates a back mutation (@) or a position that is located in an overlapping region
shared by two genes (*). Several mutational hotspot variants were not considered for phylogenetic reconstruction and therefore were eliminated
from the tree; these included variants at the homopolymeric tracks around position 310, the microsatellite at m.523–524 d (aka m.522–523 d), the
transversion m.16182A.C, m.16183A.C, m.16193+1C(C), m.16519T.C, and length or point heteroplasmies. Codes of the samples are indicated in
colored circles at the terminal branches of the phylogeny: green indicates a mutation on gene SOS1, orange indicates a mutation on PTPN11, yellow
indicates a mutation on KRAS, grey indicates lack of mutations on genes SOS1, PTPN11, KRAS, and RAF, and white indicates that data is not available
for that sample.
doi:10.1371/journal.pone.0018348.g001
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11.5 mL of the reaction mixture, containing 2.5 mL of sequenc-
ing buffer (5X), 0.5 mL of BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems), 1 mL of the corresponding
primer (final concentration was 1 mM), 3 mL of the purified
PCR product and water up to 11.5 mL. The automatic mtDNA
sequencing was carried using capillary electrophoresis ABI3730
(Applied Biosystems).
Nomenclature and quality control
The revised Cambridge Reference Sequence or rCRS [30] was
referred to for mtDNA variations. Haplogroup nomenclature was
based on previous studies [28,31,32,33,34,35]; the reference
phylogeny is being updated by the project Phylotree [36]; see
mtDNA tree Build 11 (7 Feb 2011) (http://www.phylotree.org/).
In order to reduce the impact of sequencing artefacts
[37,38,39,40] we followed the phylogenetic procedures described
in [40,41,42] which basically consisted of using the mtDNA
worldwide tree as a reference to avoid artefactual profiles and
documentation errors in mtDNA sequences and SNP genotypes as
much as possible. This approach aimed to detect artificial patterns
of mtDNA variations that significantly differed from the expected
natural ones.
Statistical analysis
Counts of different types of mutational changes were carried out
as in Elson et al. [43]. Pearson’s chi-square test was applied to 262
contingency tables. A maximum parsimony tree was built using
the genetic information from the entire mtDNA molecule
(excluding the fastest mutational variants). Relative positional
mutation rates were taken from Soares et al. [44].
All of the statistical analyses were carried out individually for
carriers and non-carriers of nDNA mutations. However, the
amount of mutations accumulated in both groups for the different
mutational categories (nonsynonymous, synonymous, tRNA, and
recurrent, among others) was statistically non-significant in all
cases (Pearson’s chi-square test, p-value.0.05). Therefore, given
that mutational patterns were almost similar for carriers and non-
carriers of nDNA mutations, the figures and tables presented in
the main text refer to the total sample size of patients. However,
for the sake of clarity, the analyses carried out separately for
carriers and non-carriers are presented in Supplementary Figures
S1, S2, S4, and S5. Analyses were also carried out for NS patients
alone, and as expected, the results were virtually the same than
those obtained for the whole sample (data not shown) given that
NS cases represented 93% of the sample.
The dataset of mtDNA profiles reported by A´lvarez-Iglesias
et al. [28] representing a typical northern Iberian population was
used as a control group for haplogroup frequency comparisons
with patients.
Results
Nuclear mutations and clinical features
Seven genes (PTPN11, SOS1, KRAS, RAF1, BRAF, SHOC2 and
MEK1, alias MAP2K1) have been causally related to NS and
closely related conditions (including LEOPARD syndrome) and
clinically related disorders (e.g. neurofibromatosis type 1) [2]. All
of our patients were screened for mutations in nuclear DNA [45;
and author’s unpublished data]. About 44% of them carried
nDNA mutations; in particular, most of them (,24%) harboured
mutations on the PTPN11 gene, and some of them on SOS1
(,18%), and KRAS (,2%) (Figure 1 and Table 1). No mutations
on the RAF1 gene were identified in negative cases of PTPN11,
SOS1, and KRAS. Patients #39 and #41 were posteriorly
diagnosed with suffering from LEOPARD syndrome, and in fact,
they carried the characteristic mutations on genes PTPN11
(Figure 1, Supplementary Table S1). Patient #35 suffered from
neurofibromatosis type 1 syndrome (NF1) and also carried a 6 Mb
deletion at 17q11-12. Nearly half of the patients suffered from
cardiopathies, especially HCM (,11%) and pulmonary valvular
stenosis (,27%). The other clinico-pathological characteristics of
the patients are summarized in Table 1.
Phylogeography and phylogeny of patient mtDNA
genomes
Entire, complete genomes were obtained for our cohort of 45
patients (Supplementary Figure S1 and Table S1). Patient mtDNA
lineages were allocated to their corresponding hgs: most of them
were of European ancestry, and therefore included representatives
of the main clades, H, V, U, K, T, J, X and N1b (Figure 1). Two
patients (patients #37 and #38; Figure 1) belonged to a still
unknown branch of haplogroup U5, here referred to as U5b1e,
Table 1. Clinico-pathological characteristics of the patients;
numbers indicate percentages of the total sample.
Phenotype Sub-phenotype/Sub-classification %
Facies
typical 40.0
suggestive 28.9
Cardiac features
typical ECG 15.6
hypertrophic cardiomyopathy 11.1
pulmonary valvular stenosis 26.7
septal isolated defects 2.2
bivalve aorta 2.2
pulmonary artery dysplasia idiopathic
dilatation
4.4
septal atrial defects 2.2
Height
percentile,3 35.6
percentile,10 17.8
Thoracic abnormalities
pectus escavatum/carinatum 26.7
broad thorax 33.3
Family history
first degree suggestive 8.9
first degree definitive 13.3
Others
mental retardation 8.9
cryptorchidism 20.0
lymphatic dysplasia 6.7
Mutation in nuclear
genes
PTPN11 24.4
KRAS 2.2
SOS1 17.8
RAF 0.0
Total 44.4
doi:10.1371/journal.pone.0018348.t001
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whereas two other patients (patients #28 and #29; Figure 1)
belonged to a new branch within H1j, here referred to as H1j1.
Two additional profiles belonged to the typical sub-Saharan hg L2
[46,47,48]. One of them fell within the sub-branch L2a1. The
other one (patient #45) described a novel branch of the L2
phylogeny referred to here as L2a5; it shared a transition at
position 7175 and a reversion at site 150 with hg L2a (Figure 1),
and most of the variants were also shared with another entire
genome uploaded in GenBank under accession number
HM596745. Another mtDNA belonged to the predominantly
North African clade M1, in particular to the branch M1a1b, a
lineage very closely related to the Sardinian-specific M1a1b1 sub-
clade [49]. The proportion of non-European lineages in our
patients mirrored the proportion expected in a typical sample of
healthy individuals from northern Iberia [28,50,51] (see Supple-
mentary Figure S1). Furthermore, the distribution of hgs was
almost identical in carriers and non-carriers of nDNA mutations
(Supplementary Figure S1). The newly discovered branches of the
mtDNA phylogeny (H1j1, U5b1e, L2a5) did not carry features
indicating an association with the NS phenotype or more
generally, with Ras/MAPK pathway syndromes (see more
analyses below).
We did not observe a correlation between the mtDNA hg
lineages of patients and whether they were positive or negative for
nuclear gene mutations (Figure 1); in other words, mutations in
nuclear genes do not seem to be correlated with the mtDNA
background of an individual. For instance, within hg H, only half
of the patients carried mutations on nuclear genes and almost all of
the carriers of nuclear mutations belonged to different sub-
branches of hg H.
In addition, patients negative for nDNA mutations showed
different mtDNA backgrounds. Therefore, there is no evidence to
indicate that basal mutations from the mtDNA tree are involved in
Ras/MAPK pathway syndromes.
The phylogenetic tree in Figure 1 shows a total of 224
substitution events occurring at the coding region (sequence range
577–16023) of the mtDNA genomes of the patients analyzed. Ten
of these were recurrent mutations (Table 2); of these, four were
nonsynonymous changes, and two of them involved the threonine
codon. The latter fits well with the estimation of Kivisild et al.
[52], indicating that most of the nonsynonymous substitutions
involved this codon. Nonsynonymous changes are more common
in the amino acid groups V, I, A, M, and T (VIAMT group; see
Figure 2), and most of the changes were between neutral apolar
amino acids (Supplementary Figure S2), as previously noted by
Pereira et al. [53] in natural populations, suggesting that these
changes in the VIAMT group are more easily tolerated than other
amino acid changes.
The percentages of changes at the first, second and third
positions of the codons were ,26%, ,11%, and ,63%,
respectively (Figure 2). This pattern resembles the one obtained
in the set of complete genomes analyzed by Pereira et al. [53],
namely: 24%, 13%, and 63%. This finding confirmed that while
the third position is under weaker evolutionary pressure than the
first and the second positions, there is a significant bias against
mutations at the second codon position.
The amino acid T and V codons were more frequently hit by
nonsynonymous changes than other amino acid codons (Figure 2),
in a proportion 1.76:1; a similar figure to the one obtained by
Kivisild et al. [52], namely: 1.7:1.
The ratio of transitions:transversion was 17.6:1 (Figure 2); this
ratio also fits well with the one obtained by Pereira et al. [53],
which was 22.2:1, when considering polymorphism over 0.1%,
which suggests the action of negative selection against transver-
sion. The spectrum of transversions followed a bias towards a
higher frequency of A and very low frequencies of G, C, and T
(7:1:3:1). A significant departure from this ratio could indicate
documentation or genotyping errors in datasets [54].
The patterns observed for mutational changes in the total
sample of patients (Figure 2) were also reproducible when the data
were analyzed separately for carriers and non-carriers of nDNA
mutations (Supplementary Figure S3).
Mutational changes in protein mtDNA genes of patients
About 33% of the variants were nonsynonymous, and they were
almost homogeneously distributed between the different protein
genes (Supplementary Figure S4). There is a quite common
misconception in medical genetic studies that tends to interpret
nonsynonymous variants as causal mutations by default. It is
possible to compare the proportion of nonsynonymous variants in
protein genes found in the mtDNA of patients with the proportion
observed in healthy individuals. For instance, if we explore the
Table 2. Homoplasmic position in the coding region mtDNAs of Ras/MAPK pathway syndromes patients.
Recurrent
position Sample ID1
Nucleotide
change
Gene
Location
Syn/Nonsyn (aa
substitution) Hg non-hg
Soares
et al. 2
709 #5*, #6, #9*, #19 G-A 12S rRNA * 3 (T, H8) 1 59
930 #1, #6 G-A 12S rRNA * 2 (M1a1b, T2b) 0 5
1719 #41*,#42*, #43 G-A 16S rRNA * 3 (N1, X2) 0 31
3010 #2, #3, #20*, #21*, #22*, #23*, #24; #25*,
#26*, #27*, #28*, #29; #30*, #31, #32
G-A 16S rRNA * 13 (H1, J1) 0 19
4674 #41*; #25*, #26* A-G ND2 Nonsyn (I-V) 0 2 2
10398 #1, #2, #3, #4*, #34, #44, #45* A-G ND3 Nonsyn (T-A) 7 (J, K1, N) 0 18
11377 #4*, #15, #16 G-A ND4 Syn 1 (J2a) 1 9
11914 #18, #44 G-A ND4 Syn 1 (L2a1’2) 1 37
13708 #2, #3, #4*, #43, G-A ND5 Nonsyn(A-T) 4 (X2b, J) 0 24
14798 #2, #3, #34 T-C CYT B Nonsyn(F-L) 3 (J1c, K) 0 7
NOTE.
1Starst identified samples carrying nDNA mutations;
2Number of mutation hits in a worldwide phylogeny as recorded in Soares et al. [44].
doi:10.1371/journal.pone.0018348.t002
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dataset of Coble et al. [55] which consists of 241 complete
genomes of mainly European ancestry (mimicking the hg
background of our patients), a total of ,33% of the variation
occurred at nonsynonymous positions, as also occurred in the
patients.
In our dataset, the ratio of nonsynonymous-synonymous
positions in the coding region was about 1:2.02 (Figure 2); this
ratio fits very well with the proportion of 1:1.97 that was obtained
previously [53] in a survey of .5100 entire genomes (see caveats
in [56]). According to Kivisild et al. [52]a ‘‘surplus of nonsynonymous
mutations is a general feature of the young branches of the phylogenetic tree’’
(p.373) [52]. In the entire mtDNAs of patients, although there was
an excess of nonsynonymous variants in young branches (n=21;
considering young branches to be the terminal ones, only) with
respect to the older ones (n=53)(see in Figure 2 ‘‘haplogroup
defining mutations’’), the difference was not statistically significant
(Pearson’s chi-square test, p-value = 0.869); these results are similar
to the ones obtained by Pereira et al. [25]. The difference was not
statistically significant when considering synonymous-nonsynon-
mous changes in the nDNA carriers (Pearson’s chi-square test, p-
value = 0.201) and nDNA non-carriers (Pearson’s chi-square test,
p-value = 0.847).
There was a high correlation (R2= 0.8) between the number of
changes that accumulated in the mtDNA coding region genes and
the length of the gene (Figure 3). This correlation was also evident
when only the synonymous changes were considered (R2 = 0.79),
but not when looking only at the nonsynonymous substitutions
(R2= 0.33) (Figure 4). However, the pattern observed for the
nonsynonymous changes fits again with the one described for the
worldwide phylogeny [53].
The accumulation of replacements per gene followed the same
trend regarding the possible maximum number of changes per
gene in carriers and non-carriers of nDNA mutations when
considering all of the changes together (regarding the length of the
genes) and when considering synonymous and nonsynonymous
changes separately (Supplementary Figure S5).
Mutational changes in tRNA mtDNA genes of patients
Mutations in tRNA genes are commonly involved in mtDNA
disorders, presumably due to their important role in protein
translation. We found ten mutations located in tRNA, most of
which were diagnostic of different hgs (Table 3). Some of these
mutations are recorded in MITOMAP (http://www.mitomap.
org/MITOMAP) as being related to some diseases, although
none of them are labelled as ‘‘confirmed’’ pathogenic mutations.
Note also that pathogenic indications in MITOMAP have to be
considered with caution given the large amount of false positives
in the literature and recorded in MITOMAP (see [20,21]). The
most conserved variants in our dataset were the m.12308A.G
and m.7561G.A transitions, according to Helm et al. [57];
however, the former is a perfect diagnostic site for the frequent
Eurasian haplogroup U and it is unlikely to be responsible for any
rare disorder, whereas the latter transition has been previously
reported in healthy individuals [58,59]. The gene that showed the
most variants in the mtDNA genomes analyzed was the tRNAThr;
this finding also fits well with the prediction of Kivisild et al. [52],
indicating that this gene bears significantly more substitutions
than any other when observing the worldwide phylogeny.
Although some of the tRNA mutations seem to be evolutionarily
well conserved, none of them have a pattern of segregation with
the disease, and none have been confirmed as pathogenic in the
literature. Taking all these results together, tRNA mutations do
not seem to play a pathogenic role in NS or related disorders
[60].
Recurrent mutations in mtDNAs of patients
As indicated in Table 2, the homoplasmic mutations did not
concentrate in particular hgs or genes; some of them were found at
Figure 2. Summary of the main features regarding different types of mtDNA changes in patients.
doi:10.1371/journal.pone.0018348.g002
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the tips of the phylogeny (see next section: private variants). Most
of these mutations are well-known hotspots in the phylogeny [44],
with the only exception of m.4674A.G that appears as a private
substitution in two patients and which received two hits in Soares
et al. [44] (Table 2). The apparent overrepresentation of tRNA
and nonsynonymous mutations among recurrent mutations was
previously observed [52] for the worldwide mtDNA phylogeny
(Table 2).
Private mutations in mtDNAs of patients
Some other variants observed in our cases were private
(Table 4) if we consider the private changes regarding their
status in the phylogeny of Figure 1 (mutations located at the
terminal branches). Nonsynonymous changes were more
common among private variants (nonsynonymous:synonymous
ratio: 1:1.91) than within haplogroup defining mutations
(1:2.08); this is because natural selection had more time to filter
out deleterious changes from the older branches than the
younger branches (see above).
Most of the private variants had already been reported in the
literature in healthy individuals, with some of them appearing
sporadically in different hg backgrounds. Some private variants
were even reported as possibly pathogenic in MITOMAP, but
this was never confirmed, with the exception of m.11778G.A, a
well-known mutation responsible for Leber hereditary optic
neuropathy LHON and progressive dystonia (patient #40;
Table 4). In addition, all of these variants appear simultaneously
as polymorphisms in MITOMAP (obviously with the exception of
m.11778G.A). Only some of the variants listed in Table 4 are
actually private and were referred to here as ‘‘novel’’, in the
understanding that ‘‘novel’’ means a variant that could not been
found in the main mtDNA databases and does not show up on
Google searches (Table 4). This ‘‘novel’’ condition alone cannot
be used to attribute a causal role to these variants; in fact, any
dataset of either healthy or unhealthy individuals will contain an
large proportion of private variants, even taking into account the
fact that there are more than 8700 complete or semi-complete
genomes available in the literature to date (http://www.
phylotree.org/). For instance, in this large dataset of entire
complete genomes, more than 60% of the transversions and 28%
of the transitions were only observed once (private substitutions).
Taking all of this evidence together, it seems unlikely that any of
the private variants observed in the patients are involved in the
NS or Noonan-like phenotypes.
Heteroplasmic variants in mtDNAs of patients
Quite often, common mtDNA diseases are related to
mutations with a heteroplasmic status. Six different hetero-
plasmies were found in the 45 patients analyzed (Table 5). Two
of them fell in the control region and were highly recurrent in
the phylogeny, especially position 16093 [44]. Only one of the
positions, 15924, fell in the tRNAThr, but this is also a well-
known mtDNA hotspot. Patient #11 carried two heteroplasmic
variants (positions 4992 and 5144), but both were synonymous
changes on gene ND2. Another position (10784) fell in the ND4
gene and was a nonsynonymous variant that changed the amino
acid isoleucine to valine, but it appeared in a healthy individual
belonging to haplogroup U6a1b (GenBank accession number:
EF064320).
Discussion
The patients analyzed in the present study (together with other
related disorders) represented the largest cohort of patients
Figure 3. Accumulation of mtDNA changes in the protein genes of patients versus size of the different genes.
doi:10.1371/journal.pone.0018348.g003
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analyzed to date by far for variations in the mtDNA molecule. The
analysis of entire, complete genomes has, for the first time, enabled
the implementation of an evolutionary approach aimed at
discovering the potential pathogenicity of mtDNA changes in
patients. The known human mtDNA phylogeny is based on 8731
complete mtDNA genomes (Phylotree), and, therefore, it provides
a solid background to compare the variation observed in the
mtDNA genomes of patients against.
Analysis of the data showed that the pattern of mutations in
tRNA genes and the pattern of nonsynonymous changes in protein
genes fit well with the variation observed in natural human
populations. In other words, replacements, substitutions and
tRNA mutations are not more prevalent in the mtDNA of
patients than expected. In addition, most of the nonsynonymous
mutations that were observed in the genomes of patients are
common polymorphisms widely distributed throughout the global
Figure 4. Accumulation of synonymous and nonsynonymous mtDNA changes in the protein genes of patients versus the maximum
number of possible changes per gene.
doi:10.1371/journal.pone.0018348.g004
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mtDNA tree. The recurrent and private mutations inferred from
the phylogeny of entire mtDNAs from patients are also as
expected, according to the patterns observed in human popula-
tions. Heteroplasmic mutations were also rare among the patients,
and the few found did not seem to play a pathogenic role given
their presence in healthy individuals too. Therefore, the
evolutionary view of entire mtDNA genomes of patients does
not support a role of mtDNA variants in the NS phenotype or in
Ras/MAPK pathway syndromes. Moreover, the pattern observed
for carriers of nuclear DNA mutations was very similar to that of
non-carriers (Supplementary Figures S1, S2, S4, and S5).
In addition, there was no prevalent mutation in our patients nor
a hg background apparently associated with the clinical pheno-
types. Therefore, the theory of a highly penetrant mtDNA
mutation being responsible for NS or Ras/MAPK pathway
syndromes can be completely disregarded by the data obtained in
the present study. In contrast to the Mendelian-like dominant
pattern observed in most Ras/MAPK pathway syndromes cases
(involving nDNA mutations), one could alternatively hypothesize a
multi-factorial (genetic) complex scenario where some phenotypes
could be explained by the sum (or interactions) of small effects
contributed by different nuclear and/or mtDNA genes. Although
the evolutionary approach employed here does not reveal the
existence of a predominant variant in patients, a population-based
approach (e.g. case-control study) could be used instead to reveal
the existence of such low risk mtDNA variants. However, such an
approach would need proper population sample sizes (in order to
obtain reasonable power to detect any positive associations, e.g.
80%), monitorization of population stratification (which is
particularly problematic in mtDNA studies) [27,61], and adequate
corrections for multiple tests, amongst others. Deficient study
designs or wrong statistical treatments of the data could easily lead
to false positives of an association. With this in mind, one could
retrospectively look to the previous evidence suggesting the weak
association between mtDNA variants and NS. The case-control
study by Castro et al. [23] represents a paradigmatic example.
These authors genotyped eight mtDNA variants in 130 Spanish
HCM patients and 300 healthy controls; note that HCM is one of
the characteristic phenotypes in NS patients (Table 1). According
to the authors, ‘‘Because multiple comparisons were taken into account (9
haplogroups and 8 SNPs), we used the Bonferroni’s correction and a p,0.01
was considered as the level of statistical significance.’’ It is not clear from
the text whether the p-value mentioned refers to the initial nominal
value or the one adjusted using Bonferroni. Either way, if one
assume an standard nominal significant value of a=0.05, an
adjusted p-nominal value using Bonferroni for 17 independent
tests (mtSNPs) would lead to a threshold for significance of 0.0029
(but not 0.01). However, Castro et al. claimed to have found a
positive association between hg T (variant G13368A) and HCM,
supported by a p-value = 0.007, which is above the correct
adjusted nominal value.
Recently, Rani et al. [24] analyzed the complete genome of
seven NS patients lacking PTPN11 mutations. They found that all
of them belonged to different sub-lineages of hg R (including
R7b1b, R30a1, R30c, T2b7, and U9a1), but the common factor
in all of them was the lack of transitions at positions 12705 and
16223 (that lead from hg N to hg R). Since the authors only
screened their patients for mutations at PTPN11 (which,
worldwide, explains about 50% of the NS cases), their patients
could have carried mutations at any of the other genes commonly
held responsible for NS [2]. The study by Rani et al. [24] does
not explain why the transitions at 12705 and 16223 should be
responsible for the NS condition. Note that hg R represents the
most common macro-hg in Europe (e.g. ,92% in northern
Iberia [28] and ,87% in our cohort of northern Iberian patients;
Pearson’s chi-square test, p-value = 0.939); and that it includes the
Table 3. Variants observed at the mtDNA tRNA genes of Ras/MAPK pathway syndromes patients.
Mutation
position Sample ID1
Nucleotide
change tRNA
Location in
secondary
structure Hg MITOMAP Conservation2
4336 #13, #14 T-C tRNA-Gln Acceptor stem H5a, U6d ADPD/hearing loss & migraine
(unclear)
50%,x,90%
7476 #4* C-T tRNA-SerUCN Anticodon stem J2 Not reported 50%,x,90%
7521 #44, #45* G-A tRNA-Asp Acceptor stem L39496, G4, M76 Not reported Different in human and
mammalian consensus
7561 #39* T-C tRNA-Asp Variable loop - Not reported 90%,x,100%
10463 #5*, #6 T-C tRNA-Arg Acceptor stem T, J1c1b1a, P4a Not reported 50%,x,90%
122853 #45* T-G tRNA-LeuCUN DHU loop L2a5 Not reported 50%,x,90%
12308 #33*, #34; #35,
#36, #37*, #38*,
#39*, #40
A-G tRNA-LeuCUN Variable loop U CPEO/stroke/CM/renal & prostate
cancer risk/altered brain pH
100%
15904 #17, #18, #19 C-T tRNA-Thr DHU loop HV0a Not reported Natural variable site
15927 #43 G-A tRNA-Thr Anticodon stem X2b, B5b, U6a5,
L0f2b, G3b,
HV1a1
Multiple sclerosis/DEAF1555
increased penetrance (P.M/
possible helper mutation)
Different in human and
mammalian consensus
15928 #5*, #6 G-A tRNA-Thr Anticodon stem T, L3x2b, C7b,
Z3a, M25, M35b
Multiple sclerosis (P.M) 50%,x,90%
NOTE.
1Starst identified samples carrying nDNA mutations;
2According to Helm et al. [57];
3Transversion 12285T.G is not actually a private variant if we consider that a new branch, L2a5, has been defined in the present article based on this entire genome and
another one previously described in the literature under the GenBank entry HM596745.
doi:10.1371/journal.pone.0018348.t003
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Table 4. Private coding region mutations observed in the entire mtDNA genomes of the patients (see Figure 1) that are ‘‘novel’’ or
are recorded in MITOMAP as (confirmed or unconfirmed) disease-associated variants.
Positions Sample ID1 Location
Nucleotide
change
Synonymous/nonsynonymous
(aa change) Haplogroup2
mtDNA Mutations with
reports of disease-
associations in MITOMAP3
827 #33* 12s rRNA A-G – G1a1a1, D4h1a2, R0a1,
B4b’d’e
Maternally inherited deafness
or aminoglycoside-induced
deafness (conflicting reports-
B4b’d marker)
961 #33* 12s rRNA T-C – M7a2b, M44, D4h2, N9a2,
A5b, R6a1a, B2i, U5a1c2,
U4a1a, L0a1b1a1, L6,
M2a1a2a1a
Maternally inherited deafness
or aminoglycoside-induced
deafness/possibly left
ventricular non-compaction-
associated (unclear)
1820 #1 16s rRNA A-G – ‘Novel’ Novel
4796*4 #36 ND2 C-T Synonymous – Novel
5029 #5* ND2 T-C (M/T) Neutral apolar-neutral polar ‘Novel’ Novel
5911 #11* COX I C-T (A-V) Neutral apolar-neutral apolar R8a1, L0a1b Prostate cancer (reported)
8544 #44 ATP6 C-T Synonymous ‘Novel’ Novel
8544 #44 ATP8 C-T (S-L) Neutral polar-neutral apolar ‘Novel’ Novel
100814 #18 ND3 T-C (M/T) Neutral apolar-neutral polar – Novel
10205 #7 ND3 C-T Synonymous ‘Novel’ Novel
11026 #17 ND4 A-G Synonymous ‘Novel’ Novel
117785 #40 ND4 G-A (R-H) Basic polar-basic polar – LHON (confirmed); progressive
dystonia (confirmed)
12103A4 #36 ND4 C-A Synonymous – Novel
14502 #33* ND6 T-C (I-V) Neutral apolar-neutral apolar M10, X2a, R8b2,
P7, N11a
LHON (reported-possible
synergistic)
14668 #19 ND6 C-T Synonymous Z2, D4, L5a1b Major depressive disorder-
associated (reported)
14831 #29 CYTB G-A (A-T) Neutral apolar-neutral polar L1c3b2 LHON (reported)
15175 #14 CYTB C-T Synonymous M9a1a1d Novel
NOTE.
1Starst identified samples carrying nDNA mutations;
2Mutations defining haplogroup(s) according to Phylotree and the data obtained here; ‘‘novel’’ means a variant that was not found in Phylotree [36], mtDB [62], HmtDB
[63], and Google searches as executed in [20,22];
3The ‘novel’ condition is as indicated in MITOMAP;
4Note that m.4796C.T and m.12103C.A were reported by Gasparre et al. [64] as novel changes in oncocytoma and CCRCC, m.4796C.T pop-up in HmtDB as reported
by Porcelli et al. [65], although this variant does not appear in the original publication, and m.10081T.C appears in Zheng et al. [66] but as generated by human pol c
in vitro;
5m.11778G.A is a well-confirmed mutation responsible for LHON and progressive dystonia, and, it fact, this pathogenic mutation appeared in a NS patient who also
suffered from LHON (see Figure 1, #40); aa: amino acid.
doi:10.1371/journal.pone.0018348.t004
Table 5. Features of heteroplasmic variants found in patients.
Position Heteroplasmy rCRS Loci Sample ID
GenBank and/or other
database searches (hg)
Soares et al.
Score
4992 G.A A ND2 #11 AP010974 (D4b2b1) 0
5144 C.T C ND2 #11 – 0
10784 G-A A ND4 #9 EF064320 (U6a1b) 1
15924 A.G A tRNAThr #15, #16 Common polymorphism 30
16286 T.C C D-loop #37 Common polymorphism 5
16093 T-C T D-loop #32 Common polymorphism 79
doi:10.1371/journal.pone.0018348.t005
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macro-hg R0 (where hg H is nested), hg U, hg J and T, amongst
others. Therefore, the observations by Rani et al. contradict the
scenario observed for our European patients: (i) our cases showed
a lower frequency of hg R than a typical control group (although
the difference was not statistically significant), and (ii) the
supposed pathogenic variants (the ones defining hg R) are the
predominant ones in Europe, an observation that is difficult to
reconcile with the prevalence of NS worldwide. As also
mentioned by Rani et al., India is very complex genetically; this
means that any study aiming to evaluate the association between
mtDNA variants and any disease should take the confounding
effect of population sub-structure into account. Finally, Rani et
al. deliberately considered hg R to be R minus U : ‘‘…followed by
hgs R and U with frequencies of 14.27%, 15.23%, respectively…’’) (p.
169) [24] and minus T (see Table 4 and Figure 3 in Rani et al.
[24]) in the controls, but they included U and T within R in cases
(as one of their patients belonged to hg U9a1 and another one to
T2b7), and thereby they artificially created more differences in
the apparent frequency between the samples than was actually
the case. Moreover, apart from U and T, their R category should
also have included the controls who belonged to hgs H2 and J1b,
because all of them shared the feature common to the rest of the
sub-lineages of hg R, which is the lack of mutations at positions
12705 and 16223. Finally, independent of possible population
stratification, any case-control study based on seven cases and
105 controls has a very low a priori power for detecting a positive
statistical association when the risk effect being looked for is weak.
Therefore, their main conclusion ‘‘The haplogroup R by itself may be
susceptible to disease phenotype or different environmental background or some
of the unidentified nuclear gene might render susceptibility to disease
phenotype…’’ (p. 171) [24] have little support in view of the
contradictions mentioned above.
On the other hand, the results and conclusions of the studies by
Dhandapany et al. [18] and Prasad et al. [19] were also critically
questioned by Bandelt et al. [21] based on two main arguments: (i)
their ‘‘novel’’ mutations were, in reality, not novel at the time of
publication, and (ii) there is little support in favour of the causal
role of these mutations in NS because most of them (if not all) are
common polymorphisms, for example, the transition of
m.2755A.G characterize hg R8. Our results agree with the
conclusions of Bandelt et al. [21]: that authors tend to overstate the
novelty of particular mtDNA variants and impute them a
pathogenic role based on this ‘‘novel’’ condition. In reality, most
of these variants were polymorphisms already known and which
are unlikely to constitute pathogenic mutations. In case-control
association studies, spurious positive associations generally show
up when using deficient statistical approaches, or when under the
presence of the population stratification, which is particularly
problematic in mtDNA association studies because its reduced
effective population sizes in comparison to average nuclear genes.
Conclusions
The analyses of replacement substitutions and other variants
observed in the patients suffering Ras/MAPK pathway syn-
dromes (tRNA, private, recurrent and heteroplasmic mutations),
as well as the pattern of hg frequencies indicated that this
variation can be fully expected as in any typical European
dataset. Changes in mtDNA genomes of patients are therefore
unlikely to be related to NS phenotype or Ras/MAPK pathway
syndromes. The combined evolutionary and phylogeographic
approach employed here seems more appropriate for evaluating
the potential pathogenicity of mtDNA variants than a case-
control study when the risk effect and the sample size are too low
to provide reasonable statistical power or when it is under the
presence of a population sub-structure.
Supporting Information
Figure S1 Haplogroup frequencies in the patients and in a typical
Iberian sample of healthy individuals [28]. For the sake of clarity,
some macro-haplogroups were sub-divided into main sub-hap-
logroups and other aggregated paragroup categories (e.g. phyloge-
netically, hg R0 should be considered as the sum of H+V+other-R0;
and U should be considered as the sum of U5+K+other-U); the
phylogenic relationships are clarified in Figure 1 and, more
generally, in the worldwide phylogeny of Phylotree.
(TIF)
Figure S2 Distribution of synonymous and nonsynonymous
changes in the mtDNA protein genes of all patients, and also
considering carriers and non-carriers of nuclear mutations
separately.
(TIF)
Figure S3 Number of different types of amino acid changes
regarding nonsynonymous substitutions.
(TIF)
Figure S4 Summary of the main features regarding different
types of mtDNA changes in the patients divided into carriers and
non-carriers of nDNA mutations.
(TIF)
Figure S5 For carriers and non-carriers of nDNA mutations:
accumulation of mtDNA changes in protein genes versus the size
of the different genes, and accumulation of synonymous and
nonsynonymous mtDNA changes in the protein genes versus the
maximum number of possible changes per gene.
(TIF)
Table S1 Mitochondrial DNA variants observed in the 45 entire
complete genomes of the patients. The notation of the variants is
explained in the legend of Figure 1. Heteroplasmic positions were
also included.
(XLS)
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